Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 April 2008, Vol. 111, No. 7, pp. 3635-3643.
Prepublished online as a Blood First Edition Paper on January 25, 2008; DOI 10.1182/blood-2007-11-123141.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-11-123141v1
111/7/3635    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azuma, T.
Right arrow Articles by Chen, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azuma, T.
Right arrow Articles by Chen, L.
Related Collections
Right arrow Immunobiology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Takeshi Azuma1, Sheng Yao1, Gefeng Zhu1, Andrew S. Flies1, Sarah J. Flies1, and Lieping Chen1

1 Department of Dermatology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

B7-H1 is an immunoglobulin-like immune suppressive molecule broadly detectable on the majority of human and rodent cancers, and its functions have been attributed to delivering an inhibitory signal to its counter-receptor programmed death-1 (PD-1) on T cells. Here we report that B7-H1 on cancer cells receives a signal from PD-1 to rapidly induce resistance against T cell–mediated killing because crippling signaling capacity of B7-H1 but not PD-1 ablates this resistance. Importantly, loss of B7-H1 signaling is accompanied by increased susceptibility to immune-mediated tumoricidal activity. In addition to resistance against T-cell destruction, B7-H1+ cancer cells also become refractory to apoptosis induced by Fas ligation or the protein kinase inhibitor Staurosporine. Our study reveals a new mechanism by which cancer cells use a receptor on immune cells as a ligand to induce resistance to therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. Melero, I. Martinez-Forero, J. Dubrot, N. Suarez, A. Palazon, and L. Chen
Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination
Clin. Cancer Res., March 1, 2009; 15(5): 1507 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Gao, X.-Y. Wang, S.-J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B.-Z. Li, Y.-H. Shi, Y.-S. Xiao, et al.
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clin. Cancer Res., February 1, 2009; 15(3): 971 - 979.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020